Nintedanib regulates miR-23b-3p/TGFBR2 axis and competitively binds to TGFBR2 protein, inhibiting EMT process in human pterygium cells
Nintedanib is found to modulate the miR-23b-3p/TGFBR2/Smad2 pathway, suggesting a novel antifibrotic mechanism. These findings collectively highlight nintedanib's therapeutic potential in managing pterygium, marking a significant step toward non-surgical treatment options. Nintedanib may offer a targeted pharmacological treatment that could complement or reduce the need for surgical interventions.
Authors
- Yan Gong (ORCID: https://orcid.org/0000-0002-3562-971X)
- Yanhong Liao (ORCID: https://orcid.org/0000-0001-6308-3120)
- Keke Zhang (ORCID: https://orcid.org/0000-0002-5755-7059)
- Xiao-Tian Liu (ORCID: https://orcid.org/0000-0001-8523-4655)
- Yongbo Bao (ORCID: https://orcid.org/0000-0002-8268-1887)
Institutions
- Ningbo University (CN)
- Zhejiang Wanli University (CN)
- Wenzhou Medical University (CN)
- Affiliated Eye Hospital of Wenzhou Medical College (CN)
Publication Details
- Journal
- International Journal of Ophthalmology
- Published
- 2025-04-23
- DOI
- https://doi.org/10.18240/ijo.2025.05.03
- Primary Topic
- Corneal Surgery and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Ningbo